These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32652570)

  • 1. Molecular and functional characterization of urine-derived podocytes from patients with Alport syndrome.
    Iampietro C; Bellucci L; Arcolino FO; Arigoni M; Alessandri L; Gomez Y; Papadimitriou E; Calogero RA; Cocchi E; Van Den Heuvel L; Levtchenko E; Bussolati B
    J Pathol; 2020 Sep; 252(1):88-100. PubMed ID: 32652570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomerular basement membrane deposition of collagen α1(III) in Alport glomeruli by mesangial filopodia injures podocytes via aberrant signaling through DDR1 and integrin α2β1.
    Madison J; Wilhelm K; Meehan DT; Delimont D; Samuelson G; Cosgrove D
    J Pathol; 2022 Sep; 258(1):26-37. PubMed ID: 35607980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
    Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR
    PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedside to bench Alport syndrome research: are human urine-derived podocytes the answer?
    Kim JJ; Fornoni A
    J Pathol; 2021 Jan; 253(1):11-13. PubMed ID: 33009821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced Pluripotent Stem Cell-Derived Podocyte-Like Cells as Models for Assessing Mechanisms Underlying Heritable Disease Phenotype: Initial Studies Using Two Alport Syndrome Patient Lines Indicate Impaired Potassium Channel Activity.
    Haynes JM; Selby JN; Vandekolk TH; Abad IPL; Ho JK; Lieuw WL; Leach K; Savige J; Saini S; Fisher CL; Ricardo SD
    J Pharmacol Exp Ther; 2018 Nov; 367(2):335-347. PubMed ID: 30104322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects.
    Abrahamson DR; Isom K; Roach E; Stroganova L; Zelenchuk A; Miner JH; St John PL
    J Am Soc Nephrol; 2007 Sep; 18(9):2465-72. PubMed ID: 17699809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial cell-specific collagen type IV-α
    Funk SD; Bayer RH; Miner JH
    Am J Physiol Renal Physiol; 2019 May; 316(5):F830-F837. PubMed ID: 30724107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.
    Ding F; Wickman L; Wang SQ; Zhang Y; Wang F; Afshinnia F; Hodgin J; Ding J; Wiggins RC
    Kidney Int; 2017 Dec; 92(6):1515-1525. PubMed ID: 28754557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for activation of the unfolded protein response in collagen IV nephropathies.
    Pieri M; Stefanou C; Zaravinos A; Erguler K; Stylianou K; Lapathitis G; Karaiskos C; Savva I; Paraskeva R; Dweep H; Sticht C; Anastasiadou N; Zouvani I; Goumenos D; Felekkis K; Saleem M; Voskarides K; Gretz N; Deltas C
    J Am Soc Nephrol; 2014 Feb; 25(2):260-75. PubMed ID: 24262798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.
    Prodromidi EI; Poulsom R; Jeffery R; Roufosse CA; Pollard PJ; Pusey CD; Cook HT
    Stem Cells; 2006 Nov; 24(11):2448-55. PubMed ID: 16873763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laminin-1 reexpression in Alport mouse glomerular basement membranes.
    Abrahamson DR; Prettyman AC; Robert B; St John PL
    Kidney Int; 2003 Mar; 63(3):826-34. PubMed ID: 12631063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine-derived podocytes-lineage cells: A promising tool for precision medicine in Alport Syndrome.
    Daga S; Baldassarri M; Lo Rizzo C; Fallerini C; Imperatore V; Longo I; Frullanti E; Landucci E; Massella L; Pecoraro C; Garosi G; Ariani F; Mencarelli MA; Mari F; Renieri A; Pinto AM
    Hum Mutat; 2018 Feb; 39(2):302-314. PubMed ID: 29098738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome.
    Ning L; Suleiman HY; Miner JH
    Am J Physiol Renal Physiol; 2021 Jul; 321(1):F12-F25. PubMed ID: 34029143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys.
    Heidet L; Cai Y; Guicharnaud L; Antignac C; Gubler MC
    Am J Pathol; 2000 Jun; 156(6):1901-10. PubMed ID: 10854213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the podocyte (and glomerular endothelium) in building the GBM.
    Abrahamson DR
    Semin Nephrol; 2012 Jul; 32(4):342-9. PubMed ID: 22958488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice.
    Kang JS; Wang XP; Miner JH; Morello R; Sado Y; Abrahamson DR; Borza DB
    J Am Soc Nephrol; 2006 Jul; 17(7):1962-9. PubMed ID: 16769745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal collagen α3α4α5(IV) trimers.
    Korstanje R; Caputo CR; Doty RA; Cook SA; Bronson RT; Davisson MT; Miner JH
    Kidney Int; 2014 Jun; 85(6):1461-8. PubMed ID: 24522496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular origins of type IV collagen networks in developing glomeruli.
    Abrahamson DR; Hudson BG; Stroganova L; Borza DB; St John PL
    J Am Soc Nephrol; 2009 Jul; 20(7):1471-9. PubMed ID: 19423686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice.
    Heidet L; Borza DB; Jouin M; Sich M; Mattei MG; Sado Y; Hudson BG; Hastie N; Antignac C; Gubler MC
    Am J Pathol; 2003 Oct; 163(4):1633-44. PubMed ID: 14507670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells.
    Daga S; Donati F; Capitani K; Croci S; Tita R; Giliberti A; Valentino F; Benetti E; Fallerini C; Niccheri F; Baldassarri M; Mencarelli MA; Frullanti E; Furini S; Conticello SG; Renieri A; Pinto AM
    Eur J Hum Genet; 2020 Apr; 28(4):480-490. PubMed ID: 31754267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.